Combining Anchor and Distribution-Based Methods to Derive Minimal Clinically Important Differences on the Functional Assessment of Cancer Therapy (FACT) Anemia and Fatigue Scales

Cella, 1997, The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale, Semin Hematol, 34, 13

Cella, 1998, Progress toward guidelines for the management of fatigue, Oncology, 12, 369

Mooney, 1991, Oncology Nursing Society research priorities survey, Oncol Nurs Forum, 18, 1381

Stetz, 1994, Oncology Nursing Society research priority survey, Oncol Nurs Forum, 22, 785

Stone, 2000, Cancer-related fatigue, Ann Oncol, 11, 971, 10.1023/A:1008318932641

World Health Organization. Cancer pain relief and palliative care. Geneva: WHO (technical report series 804), 1990.

Stone, 1998, Fatigue in patients with cancer, Eur J Cancer, 34, 1670, 10.1016/S0959-8049(98)00167-1

Cella, 1998, Factors influencing quality of life in cancer patients, Sem Oncol, 25, 43

Demetri, 1998, Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type, J Clin Oncol, 16, 3412, 10.1200/JCO.1998.16.10.3412

Jamar, 1989, Fatigue in women receiving chemotherapy for ovarian cancer

Portenoy, 1999, Cancer-related fatigue, Oncologist, 4, 1, 10.1634/theoncologist.4-1-1

Smets, 1995, The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue, J Psychometric Research, 39, 315, 10.1016/0022-3999(94)00125-O

Yellen, 1997, Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system, J Pain Symptom Manage, 13, 63, 10.1016/S0885-3924(96)00274-6

Mendoza, 1999, The rapid assessment of fatigue severity in cancer patients, Cancer, 85, 1186, 10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N

Piper, 1989, The development of an instrument to measure the subjective dimensions of fatigue

Hann, 1998, Measurement of fatigue in cancer patients, Qual Life Res, 7, 301, 10.1023/A:1008842517972

Glaspy, 1997, The impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice, J Clin Oncol, 15, 1218, 10.1200/JCO.1997.15.3.1218

Gabrilove, 2001, Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients, J Clin Oncol, 19, 2875, 10.1200/JCO.2001.19.11.2875

Littlewood, 2001, Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy, J Clin Oncol, 19, 2865, 10.1200/JCO.2001.19.11.2865

Johnson, 1985, Food and Drug Administration requirements for approval of new anticancer drugs, Cancer Treat Rep, 69, 1155

Moore, 1994, Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer, J Clin Oncol, 12, 689, 10.1200/JCO.1994.12.4.689

Thatcher, 1997, Improving quality of life in patients with non-small cell lung cancer, Eur J Cancer, 33, S8, 10.1016/S0959-8049(96)00336-X

Sloan J, Symonds T. Clinical and statistical significance: differences and similarities. Workshop presented at the International Society of Quality of Life Methods Workshop, Washington, DC, February 5–6, 2001.

Sloan JA, Cella D, Frost MH, and the Clinical Significance Consensus Meeting Group. Assessing clinical significance in measuring oncology patient quality of life: Introduction to the symposium, content overview, and definition of terms. Mayo Clinic Proc 2002;77:367–370.

Jaeschke, 1989, Measurement of health status, Control Clin Trials, 10, 407, 10.1016/0197-2456(89)90005-6

Osoba, 1998, Interpreting the significance of changes in health-related quality-of-life scores, J Clin Oncol, 16, 139, 10.1200/JCO.1998.16.1.139

Lydick, 1993, Interpretation of quality of life changes, Qual Lif Res, 2, 221, 10.1007/BF00435226

Wyrwich, 1999, Further evidence supporting a SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life, J Clin Epidemiol, 52, 861, 10.1016/S0895-4356(99)00071-2

Wyrwich, 1999, Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life, Med Care, 37, 469, 10.1097/00005650-199905000-00006

Cella, 1997

Zubrod, 1960, Appraisal of methods for the study of chemotherapy of cancer in man, J Chron Dis, 11, 7, 10.1016/0021-9681(60)90137-5

Karnofsky, 1948, The use of the nitrogen mustards in the palliative treatment of carcinoma, Cancer, 1, 634, 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L

Cohen, 1977

Norman GR, Sridhar FG, Guyatt GH, Walter SD. Reconciling effect size and MID approaches to interpretation of quality of life. Manuscript submitted for publication.

Guyatt, 1998, Interpreting treatment effects in randomized trials, BMJ, 316, 690, 10.1136/bmj.316.7132.690

Guyatt, 1993, Measuring health-related quality of life, Ann Int Med, 118, 622, 10.7326/0003-4819-118-8-199304150-00009

Bobbio, 1994, Completeness of reporting trial results, Lancet, 343, 1209, 10.1016/S0140-6736(94)92407-4

Cella, 2002, Meaningful change in cancer-specific quality of life scores, Qual Life Res, 11, 207, 10.1023/A:1015276414526